In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Anna E TsengThe National Emerging Infectious Diseases Laboratories (NEIDL), Boston University.
Prasanna Babu AravetiThe National Emerging Infectious Diseases Laboratories (NEIDL), Boston University.ORCID 0000-0002-5441-3826 Ming LoThe National Emerging Infectious Diseases Laboratories (NEIDL), Boston University.
Aoife K O'ConnellThe National Emerging Infectious Diseases Laboratories (NEIDL), Boston University.
Hans P GertjeThe National Emerging Infectious Diseases Laboratories (NEIDL), Boston University.
Anna C BelkinaThe Department of Pathology and Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118.ORCID 0000-0001-7967-6254 Colleen E ThurmanThe National Emerging Infectious Diseases Laboratories (NEIDL), Boston University.
Hirofumi KiyokawaCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA; The Pulmonary Center and Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
Darrell KottonCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA; The Pulmonary Center and Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
Shumin TanDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA.ORCID 0000-0003-1093-2576 Janice J EndsleyDepartments of Microbiology & Immunology and Pathology, The University of Texas Medical Branch, Galveston, TX 77555, USA.
William R BishaiCenter for Tuberculosis Research School of Medicine, John Hopkins University Baltimore, Maryland.ORCID 0000-0002-8734-4118 Nicholas CrosslandThe National Emerging Infectious Diseases Laboratories (NEIDL), Boston University.ORCID 0000-0003-3873-9188 Funding
Necrosis in pulmonary TB granulomas: dynamics, mechanisms, therapiesR01HL126066 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KRAMNIK, IGOR, NIEDERWEIS, MICHAEL · 2016 to 2025
$5.6MNHLBI NIH HHS R01 HL126066
6 · The paper itselfAbstract
Pulmonary tuberculosis (PTB) represents 85% of the disease burden caused by
Indexed as
epitheliumimmunityinterferonlungmacrophageTuberculosis
Identifiers
PMID40093068
PMCPMC11908135
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390